HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
26 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
EIF2AK3
eukaryotic translation initiation factor 2 alpha kinase 3
Chromosome 2 Β· 2p11.2
NCBI Gene: 9451Ensembl: ENSG00000172071.15HGNC: HGNC:3255UniProt: A0A804HIT4
288PubMed Papers
21Diseases
0Drugs
105Pathogenic Variants
FUNCTIONAL ROLE
Kinase
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
cellular response to coldeukaryotic translation initiation factor 2alpha kinase activityprotein bindingenzyme bindingWolcott-Rallison syndromecancerneurodegenerative diseaseMenkes disease
✦AI Summary

EIF2AK3 (PERK) is a metabolic-stress sensing protein kinase that serves as a critical effector of the integrated stress response (ISR) and unfolded protein response (UPR) 1. Upon sensing misfolded proteins in the endoplasmic reticulum, PERK phosphorylates eIF2Ξ±, globally attenuating cap-dependent translation while selectively promoting translation of stress-response mRNAs including ATF4 2. This phosphorylation initiates adaptive programs that reprogram cellular metabolism and proteostasis 3. Beyond classical UPR signaling, PERK functions as a direct receptor for the metabolite trimethylamine N-oxide (TMAO), activating the PERK-eIF2Ξ± axis to promote metabolic dysfunction 4. During ER stress, PERK-eIF2Ξ± signaling increases mitochondrial bioenergetics by promoting ATF4-mediated expression of supercomplex assembly factors, enhancing oxidative phosphorylation 5. Notably, mitochondrial protein ATAD3A selectively inhibits PERK signaling at mitochondria-ER contact sites, protecting mitochondrial translation from ER stress-induced repression 6. Additionally, STING-PERK-eIF2Ξ± represents a non-canonical innate immune pathway critical for cellular senescence and organ fibrosis 7. PERK dysfunction causes Wolcott-Rallison syndrome, highlighting its essential role in human health.

Sources cited
1
EIF2AK3/PERK is an effector of UPR that integrates ER stress intensity and duration to control cell fate and balance adaptive versus apoptotic responses
PMID: 29107536
2
PERK phosphorylates eIF2Ξ± under ER stress, suppressing global translation while promoting selective ATF4 translation and stress-adaptive signaling
PMID: 27211800
3
PERK-mediated UPR is dysregulated in neurodegenerative diseases characterized by protein misfolding and aggregation
PMID: 32854418
4
TMAO directly binds and activates PERK as a receptor, promoting metabolic dysfunction through FoxO1 induction
PMID: 31543404
5
PERK-eIF2Ξ±-ATF4 axis promotes respiratory supercomplex assembly and mitochondrial ATP production under nutrient and ER stress
PMID: 31023583
6
Mitochondrial ATAD3A inhibits PERK signaling at ER-mitochondria contacts, selectively protecting mitochondrial protein synthesis during ER stress
PMID: 39116259
7
STING-PERK-eIF2Ξ± represents a non-canonical innate immune pathway critical for cellular senescence and organ fibrosis
PMID: 35501370
Disease Associationsβ“˜21
Wolcott-Rallison syndromeOpen Targets
0.83Strong
cancerOpen Targets
0.53Moderate
neurodegenerative diseaseOpen Targets
0.47Moderate
Menkes diseaseOpen Targets
0.34Weak
progressive supranuclear palsyOpen Targets
0.33Weak
sialolithiasisOpen Targets
0.30Weak
uterine fibroidOpen Targets
0.27Weak
neuroinflammatory disorderOpen Targets
0.24Weak
liver diseaseOpen Targets
0.21Weak
bipolar disorderOpen Targets
0.21Weak
genetic disorderOpen Targets
0.19Weak
connective tissue diseaseOpen Targets
0.18Weak
monogenic diabetesOpen Targets
0.17Weak
neoplasmOpen Targets
0.12Weak
type 1 diabetes mellitusOpen Targets
0.11Weak
MODYOpen Targets
0.11Weak
Alzheimer diseaseOpen Targets
0.11Weak
gliomaOpen Targets
0.10Weak
achalasia-alacrima syndromeOpen Targets
0.10Suggestive
melanomaOpen Targets
0.10Suggestive
Wolcott-Rallison syndromeUniProt
Pathogenic Variants105
NM_004836.7(EIF2AK3):c.3051dup (p.Leu1018fs)Pathogenic
not provided|Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2026β†’ Residue 1018
NM_004836.7(EIF2AK3):c.1897C>T (p.Arg633Trp)Pathogenic
not provided|Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2025β†’ Residue 633
NM_004836.7(EIF2AK3):c.1564_1565del (p.Trp522fs)Pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 522
NM_004836.7(EIF2AK3):c.1578dup (p.Ala527fs)Pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 527
NM_004836.7(EIF2AK3):c.3193C>T (p.Arg1065Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 1065
NM_004836.7(EIF2AK3):c.1570_1573del (p.Lys523_Glu524insTer)Pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 523
NM_004836.7(EIF2AK3):c.1762C>T (p.Arg588Ter)Pathogenic
not provided|Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2024β†’ Residue 588
NM_004836.7(EIF2AK3):c.1306+1G>ALikely pathogenic
Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2024
NM_004836.7(EIF2AK3):c.2707C>T (p.Arg903Ter)Pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 903
NM_004836.7(EIF2AK3):c.2699del (p.Met900fs)Pathogenic
not provided|Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2024β†’ Residue 900
NM_004836.7(EIF2AK3):c.1912C>T (p.Arg638Ter)Pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 638
NM_004836.7(EIF2AK3):c.641A>G (p.Tyr214Cys)Likely pathogenic
Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2024β†’ Residue 214
NM_004836.7(EIF2AK3):c.2729_2732del (p.Glu910fs)Pathogenic
Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2024β†’ Residue 910
NM_004836.7(EIF2AK3):c.1306+1G>CLikely pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2023
NM_004836.7(EIF2AK3):c.1650+1G>ALikely pathogenic
not provided
β˜…β˜…β˜†β˜†2023
NM_004836.7(EIF2AK3):c.1192C>T (p.Gln398Ter)Pathogenic
Wolcott-Rallison dysplasia
β˜…β˜…β˜†β˜†2023β†’ Residue 398
NM_004836.7(EIF2AK3):c.2128G>T (p.Glu710Ter)Pathogenic
Wolcott-Rallison dysplasia|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 710
NM_004836.7(EIF2AK3):c.2045G>A (p.Trp682Ter)Pathogenic
Menkes kinky-hair syndrome|not provided
β˜…β˜…β˜†β˜†2020β†’ Residue 682
NM_004836.7(EIF2AK3):c.1199C>G (p.Ser400Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 400
NM_004836.7(EIF2AK3):c.3173T>C (p.Leu1058Pro)Likely pathogenic
Wolcott-Rallison dysplasia
β˜…β˜†β˜†β˜†2025β†’ Residue 1058
View on ClinVar β†—
Related Genes
PXDNLProtein interaction98%EIF2AProtein interaction98%PSEN1Protein interaction94%ACTBProtein interaction93%GAPDHProtein interaction92%CREB1Protein interaction92%
Tissue Expression6 tissues
Bone Marrow
100%
Liver
33%
Lung
32%
Heart
26%
Brain
25%
Ovary
24%
Gene Interaction Network
Click a node to explore
EIF2AK3PXDNLEIF2APSEN1ACTBGAPDHCREB1
PROTEIN STRUCTURE
Preparing viewer…
PDB4X7K Β· 1.80 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.61LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.47 [0.36–0.61]
RankingsWhere EIF2AK3 stands among ~20K protein-coding genes
  • #1,240of 20,598
    Most Researched288 Β· top 10%
  • #735of 5,498
    Most Pathogenic Variants105 Β· top quartile
  • #4,187of 17,882
    Most Constrained (LOEUF)0.61 Β· top quartile
Genes detectedEIF2AK3
Sources retrieved26 papers
Response timeβ€”
πŸ“„ Sources
26β–Ό
1
The Unfolded Protein Response and Cell Fate Control.
PMID: 29107536
Mol Cell Β· 2018
1.00
2
The Role of the PERK/eIF2Ξ±/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress.
PMID: 27211800
Curr Mol Med Β· 2016
0.90
3
Endoplasmic Reticulum Stress and Unfolded Protein Response in Neurodegenerative Diseases.
PMID: 32854418
Int J Mol Sci Β· 2020
0.80
4
A non-canonical cGAS-STING-PERK pathway facilitates the translational program critical for senescence and organ fibrosis.
PMID: 35501370
Nat Cell Biol Β· 2022
0.70
5
The critical role of endoplasmic reticulum stress and the stimulator of interferon genes (STING) pathway in kidney fibrosis.
PMID: 39566842
Kidney Int Β· 2025
0.68